1. Home
  2. GBIO vs TPST Comparison

GBIO vs TPST Comparison

Compare GBIO & TPST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GBIO
  • TPST
  • Stock Information
  • Founded
  • GBIO 2016
  • TPST 2011
  • Country
  • GBIO United States
  • TPST United States
  • Employees
  • GBIO N/A
  • TPST N/A
  • Industry
  • GBIO Biotechnology: Pharmaceutical Preparations
  • TPST Biotechnology: Pharmaceutical Preparations
  • Sector
  • GBIO Health Care
  • TPST Health Care
  • Exchange
  • GBIO Nasdaq
  • TPST Nasdaq
  • Market Cap
  • GBIO 29.2M
  • TPST 33.0M
  • IPO Year
  • GBIO 2020
  • TPST N/A
  • Fundamental
  • Price
  • GBIO $0.38
  • TPST $6.78
  • Analyst Decision
  • GBIO Strong Buy
  • TPST Hold
  • Analyst Count
  • GBIO 4
  • TPST 3
  • Target Price
  • GBIO $7.33
  • TPST $30.00
  • AVG Volume (30 Days)
  • GBIO 558.2K
  • TPST 234.4K
  • Earning Date
  • GBIO 08-06-2025
  • TPST 08-07-2025
  • Dividend Yield
  • GBIO N/A
  • TPST N/A
  • EPS Growth
  • GBIO N/A
  • TPST N/A
  • EPS
  • GBIO N/A
  • TPST N/A
  • Revenue
  • GBIO $24,556,000.00
  • TPST N/A
  • Revenue This Year
  • GBIO N/A
  • TPST N/A
  • Revenue Next Year
  • GBIO N/A
  • TPST N/A
  • P/E Ratio
  • GBIO N/A
  • TPST N/A
  • Revenue Growth
  • GBIO 146.47
  • TPST N/A
  • 52 Week Low
  • GBIO $0.32
  • TPST $5.35
  • 52 Week High
  • GBIO $3.65
  • TPST $35.23
  • Technical
  • Relative Strength Index (RSI)
  • GBIO 48.07
  • TPST 46.00
  • Support Level
  • GBIO $0.35
  • TPST $6.48
  • Resistance Level
  • GBIO $0.41
  • TPST $7.04
  • Average True Range (ATR)
  • GBIO 0.03
  • TPST 0.84
  • MACD
  • GBIO -0.00
  • TPST -0.05
  • Stochastic Oscillator
  • GBIO 30.11
  • TPST 12.96

About GBIO Generation Bio Co.

Generation Bio Co is a genetics medicine company focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable highly differentiated therapeutic applications. Its first platform is a potent, highly selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for highly selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.

About TPST Tempest Therapeutics Inc.

Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.

Share on Social Networks: